Recurrence and progression in patients with non-muscle invasive bladder cancer

Prognostic models including multicolor fluorescence in situ hybridization molecular grading

Michele Lodde, Christine Mian, Roman Mayr, Evi Comploj, Emanuela Trenti, Roberto Melotti, Fabio Campodonico, Massimo Maffezzini, Hans Martin Fritsche, Armin Pycha

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To test the prognostic value of multicolor fluorescence in situ hybridization analyses of tumor cells in urine for prediction of the recurrence and progression of tumor in patients with intermediate risk non-muscle invasive bladder cancer. Methods: A total of 168 patients with non-muscle invasive bladder cancerwere included in the study. Fluorescence in situ hybridization was carried out on the bladder wash urine collected before resection. Tumors were classified as low molecular grading if they had a diploid chromosomal pattern or only a loss of p16 or ch3 aneuploidy, and as high molecular grading if they showed aneuploidy of ch7 or 17. Cox regression models assessed the added prognostic value of fluorescence in situ hybridization for primary tumor recurrence or progression, respectively. Results: Median follow up was 67 months. A total of 57% of tumors were classified as low molecular grading. The 2- and 5-year recurrence-free survival was 68% and 49% for low molecular grading, and 47% and 30% for high molecular grading, respectively. The 2- and 5-year progression-free survival was 95% and 84% for low molecular grading, and 79% and 58% for high molecular grading tumor patients, respectively. Molecular grading (hazard ratio 1.60; P = 0.03) was associated with recurrence, when also accounting for histopathology and a patient's characteristics. Both cancer severity score (hazard ratio 1.51; P <0.01) and molecular grading (hazard ratio 2.53; P <0.01) independently and positively predicted progression in multivariable models. The C-index for predicting recurrence increased from 0.58 to 0.61 when molecular grading fluorescence in situ hybridization was included in the model, and from 0.68 to 0.72 when predicting progression. Conclusions: Fluorescence in situ hybridization-based molecular grading increases the accuracy of a prognostic model, predicting both recurrence and progression in patients with intermediate risk non-muscle invasive bladder cancer.

Original languageEnglish
Pages (from-to)968-972
Number of pages5
JournalInternational Journal of Urology
Volume21
Issue number10
DOIs
Publication statusPublished - 2014

Fingerprint

Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Recurrence
Neoplasms
Aneuploidy
Urinary Bladder
Urine
Neoplasm Grading
Diploidy
Proportional Hazards Models
Disease-Free Survival
Survival

Keywords

  • Multicolor fluorescence in situ hybridization
  • Non-muscle invasive bladder cancer
  • Prognostic model
  • Progression
  • Recurrence

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Recurrence and progression in patients with non-muscle invasive bladder cancer : Prognostic models including multicolor fluorescence in situ hybridization molecular grading. / Lodde, Michele; Mian, Christine; Mayr, Roman; Comploj, Evi; Trenti, Emanuela; Melotti, Roberto; Campodonico, Fabio; Maffezzini, Massimo; Fritsche, Hans Martin; Pycha, Armin.

In: International Journal of Urology, Vol. 21, No. 10, 2014, p. 968-972.

Research output: Contribution to journalArticle

Lodde, M, Mian, C, Mayr, R, Comploj, E, Trenti, E, Melotti, R, Campodonico, F, Maffezzini, M, Fritsche, HM & Pycha, A 2014, 'Recurrence and progression in patients with non-muscle invasive bladder cancer: Prognostic models including multicolor fluorescence in situ hybridization molecular grading', International Journal of Urology, vol. 21, no. 10, pp. 968-972. https://doi.org/10.1111/iju.12509
Lodde, Michele ; Mian, Christine ; Mayr, Roman ; Comploj, Evi ; Trenti, Emanuela ; Melotti, Roberto ; Campodonico, Fabio ; Maffezzini, Massimo ; Fritsche, Hans Martin ; Pycha, Armin. / Recurrence and progression in patients with non-muscle invasive bladder cancer : Prognostic models including multicolor fluorescence in situ hybridization molecular grading. In: International Journal of Urology. 2014 ; Vol. 21, No. 10. pp. 968-972.
@article{5de7520b242b4735b32c6d9a91968d27,
title = "Recurrence and progression in patients with non-muscle invasive bladder cancer: Prognostic models including multicolor fluorescence in situ hybridization molecular grading",
abstract = "Objective: To test the prognostic value of multicolor fluorescence in situ hybridization analyses of tumor cells in urine for prediction of the recurrence and progression of tumor in patients with intermediate risk non-muscle invasive bladder cancer. Methods: A total of 168 patients with non-muscle invasive bladder cancerwere included in the study. Fluorescence in situ hybridization was carried out on the bladder wash urine collected before resection. Tumors were classified as low molecular grading if they had a diploid chromosomal pattern or only a loss of p16 or ch3 aneuploidy, and as high molecular grading if they showed aneuploidy of ch7 or 17. Cox regression models assessed the added prognostic value of fluorescence in situ hybridization for primary tumor recurrence or progression, respectively. Results: Median follow up was 67 months. A total of 57{\%} of tumors were classified as low molecular grading. The 2- and 5-year recurrence-free survival was 68{\%} and 49{\%} for low molecular grading, and 47{\%} and 30{\%} for high molecular grading, respectively. The 2- and 5-year progression-free survival was 95{\%} and 84{\%} for low molecular grading, and 79{\%} and 58{\%} for high molecular grading tumor patients, respectively. Molecular grading (hazard ratio 1.60; P = 0.03) was associated with recurrence, when also accounting for histopathology and a patient's characteristics. Both cancer severity score (hazard ratio 1.51; P <0.01) and molecular grading (hazard ratio 2.53; P <0.01) independently and positively predicted progression in multivariable models. The C-index for predicting recurrence increased from 0.58 to 0.61 when molecular grading fluorescence in situ hybridization was included in the model, and from 0.68 to 0.72 when predicting progression. Conclusions: Fluorescence in situ hybridization-based molecular grading increases the accuracy of a prognostic model, predicting both recurrence and progression in patients with intermediate risk non-muscle invasive bladder cancer.",
keywords = "Multicolor fluorescence in situ hybridization, Non-muscle invasive bladder cancer, Prognostic model, Progression, Recurrence",
author = "Michele Lodde and Christine Mian and Roman Mayr and Evi Comploj and Emanuela Trenti and Roberto Melotti and Fabio Campodonico and Massimo Maffezzini and Fritsche, {Hans Martin} and Armin Pycha",
year = "2014",
doi = "10.1111/iju.12509",
language = "English",
volume = "21",
pages = "968--972",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Recurrence and progression in patients with non-muscle invasive bladder cancer

T2 - Prognostic models including multicolor fluorescence in situ hybridization molecular grading

AU - Lodde, Michele

AU - Mian, Christine

AU - Mayr, Roman

AU - Comploj, Evi

AU - Trenti, Emanuela

AU - Melotti, Roberto

AU - Campodonico, Fabio

AU - Maffezzini, Massimo

AU - Fritsche, Hans Martin

AU - Pycha, Armin

PY - 2014

Y1 - 2014

N2 - Objective: To test the prognostic value of multicolor fluorescence in situ hybridization analyses of tumor cells in urine for prediction of the recurrence and progression of tumor in patients with intermediate risk non-muscle invasive bladder cancer. Methods: A total of 168 patients with non-muscle invasive bladder cancerwere included in the study. Fluorescence in situ hybridization was carried out on the bladder wash urine collected before resection. Tumors were classified as low molecular grading if they had a diploid chromosomal pattern or only a loss of p16 or ch3 aneuploidy, and as high molecular grading if they showed aneuploidy of ch7 or 17. Cox regression models assessed the added prognostic value of fluorescence in situ hybridization for primary tumor recurrence or progression, respectively. Results: Median follow up was 67 months. A total of 57% of tumors were classified as low molecular grading. The 2- and 5-year recurrence-free survival was 68% and 49% for low molecular grading, and 47% and 30% for high molecular grading, respectively. The 2- and 5-year progression-free survival was 95% and 84% for low molecular grading, and 79% and 58% for high molecular grading tumor patients, respectively. Molecular grading (hazard ratio 1.60; P = 0.03) was associated with recurrence, when also accounting for histopathology and a patient's characteristics. Both cancer severity score (hazard ratio 1.51; P <0.01) and molecular grading (hazard ratio 2.53; P <0.01) independently and positively predicted progression in multivariable models. The C-index for predicting recurrence increased from 0.58 to 0.61 when molecular grading fluorescence in situ hybridization was included in the model, and from 0.68 to 0.72 when predicting progression. Conclusions: Fluorescence in situ hybridization-based molecular grading increases the accuracy of a prognostic model, predicting both recurrence and progression in patients with intermediate risk non-muscle invasive bladder cancer.

AB - Objective: To test the prognostic value of multicolor fluorescence in situ hybridization analyses of tumor cells in urine for prediction of the recurrence and progression of tumor in patients with intermediate risk non-muscle invasive bladder cancer. Methods: A total of 168 patients with non-muscle invasive bladder cancerwere included in the study. Fluorescence in situ hybridization was carried out on the bladder wash urine collected before resection. Tumors were classified as low molecular grading if they had a diploid chromosomal pattern or only a loss of p16 or ch3 aneuploidy, and as high molecular grading if they showed aneuploidy of ch7 or 17. Cox regression models assessed the added prognostic value of fluorescence in situ hybridization for primary tumor recurrence or progression, respectively. Results: Median follow up was 67 months. A total of 57% of tumors were classified as low molecular grading. The 2- and 5-year recurrence-free survival was 68% and 49% for low molecular grading, and 47% and 30% for high molecular grading, respectively. The 2- and 5-year progression-free survival was 95% and 84% for low molecular grading, and 79% and 58% for high molecular grading tumor patients, respectively. Molecular grading (hazard ratio 1.60; P = 0.03) was associated with recurrence, when also accounting for histopathology and a patient's characteristics. Both cancer severity score (hazard ratio 1.51; P <0.01) and molecular grading (hazard ratio 2.53; P <0.01) independently and positively predicted progression in multivariable models. The C-index for predicting recurrence increased from 0.58 to 0.61 when molecular grading fluorescence in situ hybridization was included in the model, and from 0.68 to 0.72 when predicting progression. Conclusions: Fluorescence in situ hybridization-based molecular grading increases the accuracy of a prognostic model, predicting both recurrence and progression in patients with intermediate risk non-muscle invasive bladder cancer.

KW - Multicolor fluorescence in situ hybridization

KW - Non-muscle invasive bladder cancer

KW - Prognostic model

KW - Progression

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84908053510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908053510&partnerID=8YFLogxK

U2 - 10.1111/iju.12509

DO - 10.1111/iju.12509

M3 - Article

VL - 21

SP - 968

EP - 972

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 10

ER -